|Infinity Pharmaceuticals Inc -- USA Stock|| |
USD 1.80 0.04 2.17%
Vice President - Finance
Ms. Melissa Hackel serves as Vice President Finance of the Company. Melissa Hackel joined Infinity in 2015 and has more than 15 years of financial experience in the pharmaceutical and medical device industry and has made financial and operational contributions throughout her career leading and developing teams to manage financial analysis in support of strategic decisionmaking. Prior to joining Infinity, Ms. Hackel served as director of finance at Takeda Pharmaceutical Company. She received a MBA from Duke University and a B.A. in political science from Bates College.
President Since 2017 MBA
The company has return on total asset (ROA)
of (27.38) %
which means that it has lost $27.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (73.91) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 11.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Infinity Pharmaceuticals Inc has Current Ratio of 5.76 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 56 people.Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 56 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.